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Dysregulated endoplasmic reticulum stress and phosphorylation of eukaryotic translation 
initiation factor 2α (eIF2α) are associated with pancreatic β-cell failure and diabetes. Here we 
report the first homozygous mutation in the PPP1R15B gene (also known as constitutive 
repressor of eIF2α phosphorylation, CReP), encoding the regulatory subunit of an eIF2α-
specific phosphatase, in two siblings affected by a novel syndrome of diabetes of youth, with 
short stature, intellectual disability and microcephaly. The R658C mutation in PPP1R15B 
affects a conserved amino acid within the domain important for protein phosphatase 1 (PP1) 
binding. The R658C mutation decreases PP1 binding and eIF2α dephosphorylation, and 
results in β-cell apoptosis. Our findings support the concept that dysregulated eIF2α 
phosphorylation, whether decreased by mutation of the kinase (EIF2AK3) in Wolcott-Rallison 
syndrome or increased by mutation of the phosphatase (PPP1R15B), is deleterious to β-cells 
and other secretory tissues, resulting in diabetes associated with multi-system abnormalities. 
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The molecular mechanisms contributing to pancreatic β-cell dysfunction and apoptosis in 
diabetes remain poorly understood. Accumulating evidence suggests that endoplasmic 
reticulum (ER) stress and aspects of the response to it contribute to β-cell failure both in type 
1 and type 2 diabetes (1-6). ER stress is defined as an imbalance between unfolded protein 
load in the ER and the organelle’s functional capacity. This activates an ER stress response, 
also known as the unfolded protein response (UPR), which reduces protein load and increases 
ER folding capacity. The UPR is an adaptive response, particularly important for the survival 
of cells with a high secretory capacity such as pancreatic β-cells. The UPR is triggered by the 
activation of ER transmembrane proteins that sense the misfolded protein accumulation in the 
ER lumen and transduce the signal to the cytoplasm. One of the canonical ER stress 
transducers is protein kinase R-like endoplasmic reticulum kinase (PERK, encoded by 
EIF2AK3). PERK phosphorylates the eukaryotic translation initiation factor 2α (eIF2α) and 
attenuates protein translation to lessen the burden of the stressed ER (1;7). The effector 
pathway downstream of PERK is tightly regulated by eIF2α dephosphorylation carried out by 
a holophosphatase complex consisting of a common catalytic subunit, protein phosphatase 1 
(PP1), and a substrate-specific regulatory subunit, PPP1R15. Two such regulatory subunits 
are known: the constitutive repressor of eIF2α phosphorylation (CReP), encoded by 
PPP1R15B, acts under basal conditions (8), while GADD34, encoded by PPP1R15A, is 
activated by eIF2α phosphorylation and feeds back negatively on PERK signaling to promote 
recovery of protein synthesis as the stress response wanes (9). The PERK pathway and its 
regulation are especially important for pancreatic β-cell function and survival (10-12). 
Homozygous mutations in EIF2AK3 cause Wolcott-Rallison syndrome, a syndromic form of 
neonatal diabetes with epiphyseal dysplasia and growth retardation, and variable other 
manifestations including microcephaly (11;13), features mirrored in Perk knockout mice (14). 
Unmitigated ER stress contributes to β-cell demise in several other monogenic forms of 
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diabetes. Mutations in the insulin gene that disrupt pro-insulin folding cause severe β-cell ER 
stress and neonatal diabetes (15). Loss of the ER co-chaperone p58
IPK
, due to DNAJC3 
mutations, leads to a syndrome with young onset diabetes (16). 
Here we report on a PPP1R15B mutation in two siblings with young-onset diabetes, 
microcephaly and short stature. The mutation, located in the PP1 binding domain (8), disrupts 
PP1 binding and eIF2α dephosphorylation and reveals that β-cell dysfunction and apoptosis 
may be caused both by too little and by too much eIF2α phosphorylation.  
 
RESEARCH DESIGN AND METHODS 
Patients  
We studied a consanguineous family from Algerian origin, with two siblings affected by 
young onset diabetes, associated with short stature, microcephaly and intellectual disability. 
The study was explained to the patients, their parents, tutors and other family members, who 
agreed to participate in the genetic study and signed informed consents. The study protocol 
was approved by the local ethics committee. Blood samples were obtained from the two 
affected siblings and two non-affected relatives (the paternal grand-mother and a paternal 
aunt) and DNA was extracted using standard procedures.  
 
Exome sequencing and analysis 
Exome sequencing was performed on the genomic platform of IntegraGen (Evry, France). 
Exons of genomic DNA of the index case (patient 1) were captured with in-solution 
enrichment methodology (SureSelect Human All Exon Kits version 2, Agilent) with the 
company’s biotinylated oligonucleotide probe library (Human All Exon v2 50 Mb, Agilent). 
Genomic DNA was then sequenced on a sequencer as paired-end 75 bases (Illumina HISEQ 
2000, Illumina, San Diego, USA). Image analysis and base calling were performed with Real 
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Time Analysis software version 1.14 with default parameters (Illumina). Bioinformatic 
analysis was performed by an in-house pipeline (IntegraGen) based on the Consensus 
Assessment of Sequence and Variation (CASAVA 1.8, Illumina) to perform alignment 
against human reference genome (GRCh37/hg19), variant calling and coverage analysis. The 
overall sequencing coverage over the whole exome was 88% and 79% for a 10X and 25X 
depth of coverage respectively, resulting in a mean sequencing depth of 64X per base. Exome 
variant analysis was then performed using an in-house python pipeline on genetic variation 
annotation results (M.D., unpublished). Variants were filtered consecutively based on their 
quality, their genotype (homozygous status), the predicted consequence on coding capacity 
(missense, nonsense, splice-site and coding insertion/deletion – inframe or frameshift), and 
for their rare status based on information available in in-house (control subjects, IntegraGen) 
and public databases (Exome Variant Server [EVS; ESP 6500], ExAC [release 0.3] and 
dbSNP v.138). Variants that were homozygous or had a minor allele frequency (MAF)>0.005 
in any in-house or public database were excluded. 
 
Variant confirmation and test for diabetes segregation in the family 
Each rare variant identified as homozygous in patient 1 by exome sequencing was confirmed 
in patient 1 and further genotyped in patient 2, in two non-affected relatives (a paternal grand-
mother and a paternal aunt) and in an unrelated healthy control subject. This was done by 
Sanger sequencing or by PCR-RFLP genotyping using specific amplification primers and 
restriction enzymes that differentiate the two alleles followed by agarose gel electrophoresis 
using standard techniques. Sequencing primers and PCR-RFLP primers/enzymes are available 
on request.  
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Sanger sequencing of PPP1R15B exons and regulatory regions 
Sanger sequencing of PPP1R15B exons (coding, 5’UTR and 3’UTR regions) and flanking 
regions of a 680 bp of promoter region and a 800 bp intronic region that shows species 
conservation and contains unspliced human ESTs (UCSC Genome browser) was performed 
by Big Dye Terminator sequencing on PCR-amplified DNA using an Applied Biosystems 
3730 DNA Sequencer (Foster City, CA, USA). PCR and sequencing primers are shown in 




Clonal rat INS-1E cells (a kind gift from Dr C Wollheim, Centre Médical Universitaire, 
Geneva, Switzerland) were cultured in RPMI medium as described (18). Male Wistar rats 
(Charles River Laboratories, Chatillon-sur-Chalaronne, France) were housed and handled 
following the rules of the Belgian Regulations for Animal Care. Rat tissues were collected 
and islets were handpicked under a stereomicroscope after isolation by collagenase digestion 
(19). β-cells were purified by autofluorescence-activated cell sorting of dispersed islet cells 
(FACS, FACSAria, BD Bioscience, Erembodegem, Belgium) and cultured as described (20). 
HEK293T cells were maintained in DMEM supplemented with 10% fetal bovine serum 
(FBS), 100 mU/ml penicillin, 100 mU/ml streptomycin and 2 mM L-glutamine.  
 
Generation of the R658C mutant PPP1R15B expression plasmid 
The R658C mutation was introduced in the PPP1R15BpEGFP_C1 plasmid (21) using Quick 
change II site directed mutagenesis kit (Agilent technologies, Santa Clara, California, USA) 
and the primers huPPP1R15B_R658C_1S: GTGGTGATGAGGATTGCAAAGGACCATGG 
and huPPP1R15B_R658C_2AS: CCATGGTCCTTTGCAATCCTCATCACCAC (bold letters 
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indicate the mutation site). This vector allows the expression of recombinant proteins fused to 
GFP at its N-terminus. After mutagenesis positive clones were sequenced (Seqlab, Göttingen, 
Germany) using the following primers to cover the entire gene: F1: 
CATGGTCCTGCTGGAGTTCGTG, F2: AGAGGAGGGGATCCACTG, F3: 
ACAGTGATGGAAATAGCGAG, F4: ATCTAGTGAGATACCTATGG, F5: 
TGAGACCCCTGAGCATAG, Rev: CACACCTCCCCCTGAAC. Plasmids containing the 
mutation, but no other change in the PPP1R15B gene, were introduced into one shot Top10 
electro competent E. coli (Invitrogen, Gent, Belgium) by electroporation. The cells were 
recovered for 1h in SOC medium, plated on LB-agar containing 50 µg/ml kanamycin and 
incubated overnight at 37
o
C. Selected colonies were grown overnight at 37°C on LB 
containing 50 µg/ml kanamycin. Plasmids were purified using the PureYield Plasmid 
midiprep kit (Promega, Leiden, the Netherlands) according to the manufacturer’s instructions. 
The DNA concentration was measured using NanoDrop 3300 (Thermo Scientific, Gent, 
Belgium). 
 
PPP1R15B over-expression and immunoprecipitation 
HEK293T cells were transfected with pEGFP-plasmid without insert (empty vector) or 
expressing WT or mutant PPP1R15B, alone or combined with a mouse PP1A expression 
plasmid using PEI reagent. After 24h the cells were lysed as previously described (8). 
Using 1 µl anti-GFP antibody bound to 15 µl protein-A sepharose resin, GFP-PPP1R15B was 
purified from equal amounts of cell lysate protein. The immunoprecipitates containing 
PPP1R15B were washed twice in lysis buffer before being resolved on a 10% SDS-PAGE gel 
and blotted onto PVDF membranes or used for dephosphorylation studies. 
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PPP1R15B immunoprecipitates were resuspended in dephosphorylation buffer containing 50 
mM Tris (pH 7), 100 mM NaCl, 0.1 mM EDTA, 0.1% Triton X-100, 1 mM DTT and 1 mM 
MnCl2 and incubated with phosphorylated eIF2α for 5 to 60 minutes at 30°C. The supernatant 
was resolved on 15% phos-tagged SDS-PAGE gel and visualized using EZblue gel staining 
reagent (Sigma-Aldrich, Dorset, England). 
 
RNA interference 
Clonal and primary rat β-cells were transfected overnight with 30 nM control siRNA (Qiagen, 
Germantown, MD, USA) or siRNAs targeting rat PPP1R15B, DP5, PUMA or Bim using 
Lipofectamine RNAiMAX (Invitrogen) as described (22). The siRNAs utilized in the present 
study are listed in Supplementary Table 2. 
 
Total RNA and mRNA extraction and real time PCR 
Poly(A)
+
 mRNA and total RNA were isolated and reverse transcribed as previously described 
(19;23). Real time PCR was performed using Rotor-Gene SyBR Green on a Rotor-Gene Q 
cycler (Qiagen) (23;24). Primers were used in a conventional PCR for preparing the 
standards. Gene expression was calculated as copies/µl (25). Expression levels were corrected 
for expression of the reference gene GAPDH. Primer sequences are provided in 
Supplementary Table 3.  
 
Western blotting 
Tissue and cell preparation was performed as previously described (26). Immunoblotting was 
done using antibodies against β-actin, P-eIF2α, eIF2α, BCL-2, BCL-XL, caspase 9, caspase 3, 
Cox IV (Cell Signaling, Leiden, the Netherlands), human α-tubulin (Sigma-Aldrich), human 
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ATF3, human PP1 (Santa Cruz, Heidelberg, Germany), cytochrome c (BD Biosciences) or 
GFP produced in rabbit. Protein detection was performed using DyLight conjugated 
secondary antibody or horseradish peroxidase-conjugated secondary antibodies and 
SuperSignal West Femto chemiluminescence revealing reagent (Thermo Scientific). 
Immunoreactive bands were detected with a ChemiDoc XRS+ system and with Image Lab 
software (BIO-RAD, Hercules, CA, USA). Protein levels were corrected for α-tubulin or β-
actin. 
 
Cell treatment and apoptosis assays 
Free fatty acid (FFA) exposure was done in RPMI 1640 medium containing 0.75% FFA-free 
BSA (Roche, Mannheim, Germany) and 1% FBS. Oleate and palmitate (Sigma-Aldrich) were 
dissolved in 90% ethanol and diluted 1:100 to a final concentration of 0.5 mM (27;28). 
Cyclopiazonic acid (CPA) was used at 25 µM, tunicamycin at 5 µg/ml and brefeldin-A at 0.1 
µg/ml. The PERK inhibitor GSK2606414 was used at 0.5 µM (29). Apoptotic cell death was 
detected and counted by fluorescence microscopy after Hoechst 33342 (5 µg/ml; Sigma-
Aldrich) and propidium iodide (5 µg/ml) staining (28;30).  
 
Glucose-stimulated insulin secretion 
Insulin secretion was measured as described (22). Briefly, INS-1E cells were washed with 
modified Krebs-Ringer bicarbonate HEPES solution (KRB), incubated for 30 min with KRB 
without glucose, and insulin secretion was induced by 30 min incubation with KRB 
containing 1.67 or 16.7 mM glucose with or without 10 µM forskolin. Insulin was measured 
by ELISA (Mercodia, Uppsala, Sweden) in cell-free supernatants and acid-ethanol extracted 
cell lysates. Total protein was measured in cell lysates using the Protein Assay Dye Reagent 
(Biorad). 
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Cytochrome c release 
Cells were harvested in PBS 48h after transfection. After centrifugation, cytosolic lysis buffer 
containing 0.8 µg/µl digitonin was added to the pellet. The cells were vortexed for 30s and 
centrifuged at 4°C at 20 000 Xg for 1 minute. The supernatant was separated as cytoplasmic 
fraction and the pellet was used as the mitochondrial fraction. Laemmli buffer was added and 
the samples were resolved on 12% SDS-PAGE.  
 
Statistical analysis 
Data are presented as means ± SE. Given the paired nature of the experimental design, 
comparisons between groups were made by two-sided Student’s paired t test, with Bonferroni 




Description of a novel diabetes syndrome with young onset diabetes, short stature and 
microcephaly 
We studied two siblings with young onset diabetes, intellectual disability, microcephaly and 
short stature who were born to non-diabetic first-cousin consanguineous parents (see Table 1 
and Fig. 1 for the description of the patients). The index case (patient 1), a boy, was 
diagnosed with diabetes at age 15 years, with acute onset of polyuria and polydipsia. Fasting 
glucose was 13.4 mmol/l and HbA1c was 13.0% (119 mmol/mol). Type 1 diabetes specific 
autoantibodies (ICA, GAD, IA2) were negative. Fasting C-peptide was low but within normal 
range for normoglycemic subjects (Table 1), showing that at least some residual β-cell mass 
remained. He was treated by two daily insulin injections. Diabetes was initially well 
controlled with relatively low doses of insulin (~0.5 U/kg/day), but evolved to significant 
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glucose variability with severe hypoglycemia episodes and seizures. He had growth 
retardation (Fig. 1A), reaching adult height of 1.55 m, with normal growth hormone (GH peak 
at 41 ng /ml after ornithine stimulation test; N: >10) and IGF1 levels (291 µg/l; N:249-672). 
Thyroxine (18 pmol/l; N:10-23) and glucagon (116 ng/l; N:25-250) levels were normal. 
Blood cell count, electrolytes, creatinine, liver enzymes, bilirubin, cholesterol, triglycerides, 
lactate and pyruvate levels were normal. He had delayed puberty, with undescended right 
testis that was surgically corrected. No anomaly of the gonadal function was found, with 
normal levels of testosterone (9.54 nmol/l; N:9.0-26.0), LH (4.4 mU/ml; N:0.24-5.9) and FSH 
(6.5 mU/ml; N:1.9-11.6). He had microcephaly (adult cranial perimeter: 46 cm, -4.0 SD) and 
severe intellectual disability, with a quiet introverted character. At 15 years his mental level 
was comparable to that of a 5-6-year-old child. He answered questions using simple sentences 
but could not read or write. His vocabulary was limited to 200–300 words and he did not 
engage in conversation. He was able to perform tasks such as feeding, dressing and bathing 
but required full assistance in daily life. Magnetic resonance imaging showed rarefaction of 
the white matter (Fig. 1B), with non-specific slightly elevated level of protein in the 
cerebrospinal fluid (albumin and IgG). He had neurogenic deafness (hearing loss of 39%). He 
also had kyphoscoliosis, pectus excavatum and mild abnormalities of vertebral bodies (Fig. 
1C and D), fine fingers and toes, oligodenty and dental hypoplasia, sparse hair and a high-
pitched voice. Eye fundus was normal. Clinical and biochemical examination at 28 years 
showed that his diabetes was relatively well controlled (Table 1). Glucagon-stimulated C-
peptide was detectable. Pubertal development was fully achieved (Tanner stage 5) with adult 
genitalia and complete epiphyseal closure on bone age X-ray. Biochemical measurements in 
serum showed low 25-hydroxyvitamin D (55 nmol/l; N:75-340), but normal levels of calcium, 
IGF-1 and thyroxine. Markers of phosphate metabolism were normal: PTH (19 pg/ml; N:10-
55); serum phosphate (1.54 mmol/l; N:1.30-1.85); alkaline phosphatase (320 U/l; N:210- 
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830). Urinary calcium to creatinine ratio was also normal (0.33; N<0.7). His weight and BMI 
were low at 44.3 kg and 18.4 kg/m
2
, respectively. Dual-energy X-ray absorptiometry showed 
normal body composition and bone mineral content. Overall, these results are in keeping with 
bone dysplasia without marked disturbance of calcium metabolism, with severe growth 
retardation unrelated to pituitary or thyroid dysfunction. Serum amylase, blood cell count, 
liver and kidney function and iron metabolism were normal. On ultrasound, liver and 
pancreas were normal, while the kidneys were small, with mild dilation of right calyces. 
His sister (patient 2) had a similar clinical presentation, but she was not available for detailed 
evaluation. She had growth retardation, microcephaly, intellectual disability and diabetes 
presenting with an acute onset of hyperglycemia and ketosis at age 28 years. She was treated 
by insulin. She also had dental hypoplasia, an introverted character and high-pitched voice. 
She had menarche at the age of 14 years. At the last examination at 31 years, body weight was 
30 kg, height 139 cm, BMI 15.5 kg/m
2
 (Table 1). Blood cell count, electrolytes and kidney 
function parameters were normal. Early clinical history was unavailable for these patients, 
except for the information that they were born small for gestational age. The parents had 
normal fasting glucose (father: 5.1 mmol/l, mother: 4.3 mmol/l; N<5.6) and the mother was 
not known to have had gestational diabetes. They were unavailable for further clinical 
examination and genetic study.  
 
Identification of a homozygous mutation in the PPP1R15B gene in the two diabetic 
siblings 
Because of the familial context, we hypothesized that the syndrome was caused by an 
autosomal recessive mutation. To test this hypothesis, we performed exome sequencing on 
patient 1’s genomic DNA and identified 18 rare homozygous autosomal variants after 
filtering (coding variants, minor allele frequency <0.005 and absence of subjects homozygous 
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for the rare variant in public and in-house databases; Supplementary Tables 4 and 5). We 
confirmed these variants in patient 1 and genotyped them in patient 2 and in two non-affected 
relatives (a grandmother and an aunt) by Sanger sequencing or PCR-RFLP genotyping. This 
reduced the number of variants to 6, for which both siblings, but not the unaffected relatives, 
were homozygous for the rare allele: ADAMTSL4, FLG, KIF21B, PPP1R15B, and SLC45A3, 
located on chromosome 1, and UNC80, located on chromosome 2 (Supplementary Tables 5 
and 56). Because of the relative similarities of this syndrome with Wolcott-Rallison syndrome 
(EIF2AK3 mutations), the features of the Ppp1r15b
-/-
 mouse (very small size at birth and early 
death) and its role in the ER stress response (31), PPP1R15B (Fig. 2A) appeared as the major 
candidate (Supplementary Table 6). None of the other genes showed obvious functional 
relevance to the syndrome (Supplementary Table 6). PPP1R15B is ubiquitously expressed 
(and well expressed in human islets and β-cells), consistent with the multi-system disease 
manifestations, while the other genes have a lower expression in islets, and their pattern of 
tissue expression does not specifically correspond to the syndrome (Supplementary Fig. 1, 
Supplementary Table 6). The R658 residue of PPP1R15B is highly conserved between 
organisms, including viruses (Fig. 2B) and the R658C mutation is predicted to be damaging 
by in silico prediction programs (Supplementary Table 6). It is located in the conserved C-
terminal functional core of PPP1R15B that specifies interaction with PP1, the recruitment of 
the essential co-factor G-actin and substrate-specific dephosphorylation (21;32). In the co-
crystal structure, PPP1R15B R658 inserts deep into a pocket on the surface of PP1 (34), 
giving rise to an ionic interaction with PP1 residue D71 that is conserved in other 
holophosphatases such as PP1-PPP1R10 (PNUTS) and PP1-PPP1R9B (spinophilin) (33). 
Collectively, these structural observations strongly support a critical role of R658 in PP1 
binding and predict that mutation of this residue has deleterious effects on protein function. 
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To search for additional patients with PPP1R15B mutations, we performed Sanger 
sequencing of PPP1R15B exons, flanking regions, and main regulatory regions 
(Supplementary Table 1) in 50 patients with a similar clinical presentation, i.e. insulin-
dependent diabetes and short stature and/or [mental retardation or microcephaly] and in 22 
diabetic patients and their families compatible with monogenic diabetes and linkage to the 
PPP1R15B chromosome region (C.J., unpublished data), but we did not identify any 
homozygous or compound heterozygous PPP1R15B mutation in these patients.  
 
The R658C mutation destabilizes the PPP1R15B-PP1 complex and impairs eIF2α 
dephosphorylation 
To study the effect of the R658C mutation on PPP1R15B function we generated a plasmid 
encoding the fusion of wild-type (WT) or R658C mutated human PPP1R15B to EGFP. 
HEK293T cells were transfected with either plasmid or the empty pEGFP vector, alone or in 
combination with a plasmid expressing mouse PP1A. The PPP1R15B-PP1 complex was 
immunoprecipitated from cell lysates using anti-GFP antibody and analyzed for the presence 
of PP1 by Western blot. Less PP1 was recovered in complex with mutant PPP1R15B-EGFP 
compared to WT. This was true both when endogenous PP1 was examined (compare lanes 1 
and 2, Fig. 3A) and when PP1A was overexpressed (compare lanes 5 and 6, Fig. 3A), 
demonstrating that the R658C mutation reduced the ability of PPP1R15B to bind PP1, as 
suggested by the structural studies.  
Next we examined the dephosphorylation activity of the immunopurified PPP1R15B-PP1 
holophosphatase complex. Complexes recovered by immunopurification of GFP-tagged WT 
PPP1R15B were more active at dephosphorylating eIF2α in vitro than complexes constituted 
of the R658C mutant (compare lanes 4 and 5 in Fig. 3B). These differences were rendered 
more conspicuous in a time course study: Complexes containing WT PPP1R15B substantially 
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dephosphorylated eIF2α protein by 45 minutes, whereas in dephosphorylation reactions 
carried out with R658C mutant PPP1R15B, substantial amounts of phosphorylated eIF2α 
remained even at the 60 minute time point (compare lanes 7 and 12, Fig. 3C). Thus, the 
missense mutation R658C negatively affects the stability of the PPP1R15B-PP1 complex and 
in turn its ability to dephosphorylate eIF2α. 
 
PPP1R15B expression in β-cells 
In clonal rat INS-1E β-cells PPP1R15B was induced by different synthetic ER stressors and 
the saturated FFA palmitate (Fig. 4A). This induction was prevented by a chemical inhibitor 
of PERK (Fig. 4B), suggesting that, different from other cell types (8), PPP1R15B expression 
in β-cells is controlled by the UPR. 
 
PPP1R15B deficiency increases eIF2α phosphorylation in β-cells 
Using RNA interference, PPP1R15B was knocked down in INS-1E cells, resulting in a 75% 
inhibition of mRNA expression (Fig. 4C). Consistent with its previously reported function of 
constitutive eIF2α phosphatase (8), basal eIF2α phosphorylation was increased in PPP1R15B-
deficient INS-1E cells (Fig. 4D and E). PPP1R15B silencing did not further increase eIF2α 
phosphorylation induced by the synthetic ER stressor CPA or palmitate (Fig. 4D and E). P-
eIF2α levels were higher in PPP1R15B-deficient cells exposed to the unsaturated FFA oleate 
that per se does not induce eIF2α phosphorylation (28;34). ATF3 protein was also induced in 
PPP1R15B-deficient cells under basal condition (Fig. 4F and G). Thus, PPP1R15B silencing 
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PPP1R15B silencing decreases insulin content and glucose-stimulated insulin release 
We next evaluated the effect of PPP1R15B deficiency on β-cell function. PPP1R15B 
knockdown decreased insulin content in INS-1E cells by 20% (Fig. 5A). In control siRNA 
transfected β-cells, high glucose exposure (16.7 mM) increased insulin secretion by 2.8-fold. 
PPP1R15B-deficient β-cells showed increased basal insulin secretion, and little or no 
response to high glucose (Fig. 5B). 16.7 mM glucose plus forskolin induced insulin secretion 
by 10-fold in control siRNA transfected cells, but only by 4-fold after PPP1R15B silencing 
(p<0.05). 
 
PPP1R15B-deficient β-cells are sensitized to apoptosis through the pro-apoptotic BH3-
only proteins DP5, PUMA and Bim 
We examined the role of PPP1R15B in β-cell survival. PPP1R15B silencing in clonal (Fig. 
6A and B) and primary rat β-cells (Fig. 6C) sensitized the cells to apoptosis under basal 
condition, and induced up to 20% more apoptosis following exposure to CPA or the FFAs 
oleate and palmitate (Fig. 6A-C). 
To evaluate whether the intrinsic pathway of apoptosis was involved we measured 
mitochondrial cytochrome c release to the cytoplasm and cleavage of caspase-9 and -3. In 
PPP1R15B-deficient INS-1E cells, cytoplasmic cytochrome c levels were increased (Fig. 6D), 
and caspase-9 (Fig. 6E) and -3 (Fig. 6F) were cleaved, demonstrating activation of the 
intrinsic pathway of apoptosis. 
We next examined which BCL-2 family members activate the intrinsic pathway of apoptosis. 
PPP1R15B deficiency induced mRNA expression of the pro-apoptotic proteins DP5 and 
PUMA (Fig. 6G and H), but it did not significantly affect expression of Bim-S protein (Fig. 
6I). The expression of Bim-L and EL (Supplementary Fig. 2A-C) and the anti-apoptotic 
proteins BCL-2 and BCL-XL (Supplementary Fig. 2D-F) was not modified by PPP1R15B 
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deficiency. DP5, PUMA or Bim silencing partially protected PPP1R15B-silenced β-cells from 
apoptosis (Fig. 6J), showing that PPP1R15B deficiency induces apoptosis through the pro-




R658C is the first reported mutation in PPP1R15B, responsible for a novel diabetes syndrome 
with onset in youth/young adulthood. It affects a key amino acid in the conserved C-terminus 
region of the protein that makes contacts with PP1 that is conserved in other holophosphatase 
complexes (32;33). We presently show that the R658C mutation destabilizes the complex 
between PPP1R15B and PP1 and this in turn diminishes eIF2α dephosphorylation. 
Furthermore, we show that PPP1R15B silencing alters β-cell function, inducing higher basal 
insulin secretion and reducing high glucose responsiveness, which is compatible with a role of 
PPP1R15B in exocytosis (35). This is consistent with the observation of residual C-peptide in 
the index patient, his moderate insulin requirement and frequent hypoglycemic events. 
PPP1R15B silencing also sensitizes β-cells to apoptosis, both under basal and ER stress 
conditions, which was induced via the intrinsic pathway of apoptosis, as in the case of 
palmitate-induced eIF2α phosphorylation (36).  
Of note, diabetes manifested relatively late in these patients (at ages 15 and 28 years). 
Considering the congenital nature of the defect, this suggests the role of compensatory 
mechanisms that maintain a sufficient β cell function for several years. The acute onset of 
diabetes suggests a threshold mechanism(s), by which this delicate balance is disrupted at 
some stage, as observed in autoimmune T1D and other forms of monogenic diabetes, leading 
to hyperglycemia (37). 
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The syndrome caused by the PPP1R15B-R658C mutation results in multisystem 
manifestations, affecting β-cells (diabetes), the nervous system (microcephaly, intellectual 
disability and hearing loss), bone (bone deformities) and general development. This 
phenotypic spectrum has interesting overlap with other mutations affecting the levels of ER 
stress or the response to it. Hence, β-cell dysfunction, bone abnormalities, microcephaly and 
intellectual disability are shared with Wolcott-Rallison syndrome caused by EIF2AK3 
mutations, that lead to higher levels of ER stress associated with less eIF2α phosphorylation 
(11;13;38), and in syndromes caused by mutations in the ER co-chaperone DNAJC3 and in 
the immediate early response 3 interacting protein 1 (IER3IP1), that both lead to higher levels 
of ER stress with more eIF2α phosphorylation (16;39;40). These commonalities likely reflect 
the importance of balanced ER protein synthesis and folding to the function of secretory cells, 
with insulin-producing β-cells, collagen-producing bone cells and nerve cells especially 
vulnerable to imbalance. In Wolcott-Rallison syndrome (with decreased eIF2α 
phosphorylation) neonatal diabetes is due to β-cell loss and C-peptide is undetectable (13), 
while DNAJC3, IER3IP1 and PPP1R15B mutations (with increased eIF2α phosphorylation) 
lead to permanent neonatal or young onset diabetes with residual C-peptide levels ((16;40) 
and this report). It is notable that mutations affecting the target of phosphorylated eIF2α, the 
guanine nucleotide exchange factor eIF2B, feature prominent neurodegenerative 
manifestations known as CACH (childhood ataxia with central nervous system 
hypomyelination)/VWM (leukoencephalopathy with vanishing white matter) syndrome (41), 
which are phenocopied by targeted activation of the eIF2α kinase PERK in the brain (42). 
Interestingly, severe forms of CACH/VWM also have multi-organ manifestations (41;43). 
The clinical variability of syndromes associated with dysregulated eIF2α phosphorylation 
likely results from the interplay of several factors including the extent of apoptosis and/or 
Page 18 of 81
For Peer Review Only
Diabetes
 19
secretory dysfunction resulting from specific genes mutations, the severity of the mutation 
and possibly environmental stresses.  
The clinical features of PPP1R15B mutated patients described here and the phenotype of 
knockout mice that we described previously (31) suggest that PPP1R15B deficiency affects 
multiple cell types. The role of PPP1R15B in exocytosis and membrane traffic has been 
previously reported in human epithelial cells and erythroleukemia cells (35). Knockdown of 
PPP1R15B in breast cancer cells resulted in impaired cell cycle transition from G1 to S phase 
and apoptosis (44). These observations suggest that PPP1R15B regulates a variety of 
functions in different cell types. More studies are needed to explore this further. 
Although we selected PPP1R15B as an obvious candidate gene, and found ample structural 
and functional experimental support for the impact of the mutation, we cannot formally 
exclude that one of the rare variants homozygous in the two affected siblings contributes to 
the syndrome. This hypothesis is unlikely based on the following reasons (Supplementary 
Table 6 and Supplementary Fig. 1): 1) None of the other genes appears directly functionally 
relevant to the clinical presentation; 2) The expression pattern of PPP1R15B, but not of the 
five other genes, is consistent with the multisystem presentation of the syndrome; 3) 
Mutations in ADAMTSL4 cause ectopia lentis, while mutations in FLG cause atopic dermatitis 
and ichtyosis vulgaris; none of these diseases were present in the two affected siblings; 4) 
Human or mouse disease phenotypes of KIF21B, SLC45A3, and UNC80 mutations have not 
been reported so far, and a cellular phenotype of chromosome instability has been reported in 
Kif21b
-/-
 mice, which was not observed in our patients. In short, the characteristics of these 
five other genes show little relevance to the diabetes and neurological phenotype of our 
patients.  
The present human genetic observations are in keeping with our earlier findings that 
excessive eIF2α phosphorylation is poorly tolerated by β-cells. Salubrinal, a chemical 
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inhibitor of eIF2α dephosphorylation, was identified in a large-scale chemical screening as a 
compound that protects from ER stress (45) and it was even suggested as a potential therapy 
to preserve β-cells in diabetes (46). In rodent and human β-cells, however, salubrinal actually 
exacerbates cell death through ER stress and downstream activation of the mitochondrial 
pathway of apoptosis (10;24). The present observations support the concept that dysregulation 
of eIF2α phosphorylation, either excessive (PPP1R15B, DNAJC3 and IER3IP1 mutations) or 
diminished (EIF2AK3 mutations), is detrimental to β-cells, neurons and bone and suggest that 
other proteins involved in the regulation of protein translation may lead to similar diabetes 
syndromes. 
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Table 1: Clinical and biochemical characteristics of the two patients 
 Patient 1 Patient 2 
Gender Male Female 
Age at diabetes onset, years 15 28 
Age at follow-up examination, years 15* 28 31 
Anthropometry    
   Height, cm (SD) 146 (-3.5) 155 (-3.2) 139 (-4.2) 
   Weight, kg (SD) 31.4 (-3.2) 44.3 (-3.5) 30 (-4.0) 
   BMI, kg/m2 (SD) 14.7 (-2.7) 18.4 (-1.7) 15.5 (-2.5) 
   Microcephaly Yes Yes Yes 
   Cranial perimeter, cm (SD) 46 (-4.0) 46 (-4.0) NA 
Glucose metabolism    
   HbA1c, % [N: 4.0-6.0] 13.0 7.8 NA 
   C-peptide secretion evaluation    
   Glycemia, fasting, mmol/l [N: <5.6] 3.96 11.4 NA 
   C-peptide, fasting, nmol/l [N: 0.25-1.28] 0.56 NA NA 
   C-peptide, glucagon-stimulated [N: >0.6] NA 0.89 NA 
Therapy    
   Insulin therapy duration, years 0 13 3 
   Insulin dose, U/kg/day 0 0.5 0.7 
Notes: * at diabetes onset. BMI = Body mass index; NA = not available. N: Normal reference 
values. Standard deviations (SD) are based on French normative values. 
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Figure 1: Imaging of brain and skeleton of patient 1. A. Growth chart, showing growth 
retardation. B. Coronal T2-weighted brain magnetic resonance imaging at age 15 years, 
showing a moderate white matter rarefaction characterized by increased sulcal size and 
moderate enlargement of ventricular system. C, D. Skeletal radiographies at age 28 years, 
showing kyphoscoliosis with tall vertebral bodies and hyperlordosis.  
 
Figure 2: Identification of a homozygous PPP1R15B-R658C mutation in two diabetic 
siblings and consequences of the mutation on the protein. (A) Sanger sequencing of a 
control subject and the two diabetic siblings (filled symbols), presenting the homozygous 
mutation and its consequence on the cDNA and protein. (B) PPP1R15B protein sequence, 
showing the alignment of a highly conserved 62 amino-acid segment (hatched) located within 
the C-terminal functional core region (gray). Representative sequences aligned are PPP1R15B 
from human (PR15B_HUMAN, Q5SWA1) and mouse (PR15B_MOUSE, Q8BFW3), 
PPP1R15A from human (PR15A_HUMAN, O75807), mouse (PR15A_MOUSE, P17564) 
and drosophila (PR15A_DROME, Q9W1E4), and homologous proteins from a variety of 
viruses: African Swine fever virus (VF71_ASFB7, Q65212), Amsacta moorei 
entomopoxvirus L (NP_064975), Glossina pallidipes salivary gland hypertrophy virus 
(YP_001687092), Choristoneura occidentalis granulovirus (YP_654457) and Trichoplusia 
niascovirus 2c (YP_803309). The mutated Arginine (R) at position 658 is part of the 
functional RVxF-ΦΦ-R motif (boxed and underlined on human PPP1R15B), that has been 
recognized in PP1 interacting proteins (33). Residues shown in red are fully conserved in 
selected species; residues that are the most critical for establishing contact with PP1 according 
to Chen et al. (32) are indicated by stars.  
 
Page 30 of 81
For Peer Review Only
Diabetes
 31
Figure 3: The R658C mutation destabilizes the PPP1R15B-PP1 complex and diminishes 
its phosphatase activity. HEK293T cells were transfected with an empty vector (GFP) or a 
GFP-tagged wild-type (WT) or R658C mutated (Mut PPP1R15B) human PPP1R15B, alone 
or in combination with a mouse PP1A expression plasmid. PPP1R15B-PP1 complexes were 
immunoprecipitated from lysed cells with anti-GFP antibody. (A) The recovery of PP1 in 
complex with PPP1R15B was examined by Western blotting using anti-PP1 antibody. 
Immunoprecipitated protein is shown on the left (IP) and the eluent is shown on the right 
(input). (B) The holophosphatase activity was studied in an eIF2α dephosphorylation assay, 
incubating the indicated PPP1R15B-PP1 complexes purified from cells with in vitro 
phosphorylated P-eIF2α protein for 30 min and resolving the phosphorylated and non-
phosphorylated eIF2α on PhosTag gels. (C) A time course of eIF2α dephosphorylation by 
WT and Mut PPP1R15B-PP1A complexes recovered by immunopurification from transfected 
HEK293T cells. Unphosphorylated eIF2α was loaded onto lane 1 as a reference. The blots are 
representative of 3 or more independent experiments with similar outcomes. 
 
Figure 4: PPP1R15B is induced by ER stress in β-cells in a PERK-dependent manner 
and PPP1R15B silencing induces eIF2α phosphorylation and ATF3 in β-cells. (A) INS-
1E cells were exposed to the chemical ER stressors CPA, tunicamycin (TU) or brefeldin A 
(BR), or the FFAs oleate (OL) or palmitate (PAL) for 24h (n=5-6). (B) INS-1E cells were 
exposed or not (CT) to CPA in the presence or absence of the PERK inhibitor GSK2606414 
(PERKi). PPP1R15B mRNA expression was examined by real time PCR and normalized to 
the reference gene GAPDH. (C) INS-1E cells were transfected with control siRNA (siCT) or 
two different siRNAs targeting PPP1R15B (P1R15B1 and P1R15B2). 48h after transfection 
the cells were treated for 16h with CPA, oleate (OL) or palmitate (PAL). PPP1R15B mRNA 
expression was examined by real time PCR and normalized to the reference gene GAPDH 
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(n=4). eIF2α phosphorylation (P-eIF2α) (D, E) and ATF3 (F, G) expression were examined 
by Western blot. (D) and (F) are representative images of n=4. (E) and (G) represent 
densitometric quantifications of (D) and (F) respectively. P-eIF2α was corrected for total 
eIF2α. ATF3 expression was corrected for α-tubulin and expressed as fold of CT. Data are 
presented as means ± SE. *treated vs control, §DMSO vs PERKi, #siP1R15B vs siCT by two-
sided Student’s paired t test, */§/#p<0.05, **/##p<0.01, ***/###p<0.001 
 
Figure 5: Glucose-stimulated insulin secretion is blunted by PPP1R15B deficiency in β-
cells. INS-1E cells were transfected with control siRNA (siCT) or two siRNAs targeting 
PPP1R15B (siP1R15B1 and siP1R15B2). 48h after transfection insulin secretion was induced 
by 1.67 or 16.7 mM glucose or 16.7 mM glucose + 10 µM forskolin (16.7+FK). (A) Cellular 
insulin content corrected for total protein. (B) Insulin release as percent of insulin content 
(n=5). *vs 1.67 mM glucose, **p<0.01, ***p<0.001. #siP1R15B vs siCT, #p<0.05, ##p<0.01 
as indicated by the bars. 
 
Figure 6: PPP1R15B deficiency sensitizes β-cells to FFA- and ER stress-induced 
apoptosis and activates the intrinsic pathway of apoptosis via DP5, PUMA and Bim-S. 
INS-1E (A, B) or primary rat β-cells (C) were transfected with a control siRNA (siCT) or two 
different siRNAs targeting PPP1R15B (siP1R15B1 and siP1R15B2). 24h after transfection 
the cells were exposed or not (CT) to CPA, oleate (OL) or palmitate (PAL) for 16 (A, B) or 
24h (C) (n=4-5). (D) Mitochondrial cytochrome c release was detected by Western blot in the 
cytoplasmic fraction 48h after PPP1R15B knockdown. The right lane shows a non-
cytoplasmic fraction that includes mitochondria. Cox IV was used as mitochondrial control 
and β-actin as cytoplasmic control. Activation of caspase-9 (Casp9) (E) and -3 (Casp3) (F) 
was detected by Western blot 48h after PPP1R15B knockdown. β-actin and α-tubulin were 
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used as loading controls. D, E and F are representative blots of 4-5 experiments. The 
densitometry data were normalized to the highest value. DP5 (G) and PUMA (H) mRNA 
expression was measured by real time PCR and corrected for the reference gene GAPDH 
(n=4). Bim-S levels were measured by Western blot (Supplementary Fig. 2), corrected for α-
tubulin and expressed as fold of siCT (I) (n=5). (J) PPP1R15B was silenced alone or in 
combination with DP5, PUMA or Bim and apoptosis was examined by 
Hoechst33342/propidium iodide staining (n=3-4). *treated vs control, *p<0.05, **p<0.01, 
***p<0.001. #siP1R15B vs siCT, #p<0.05, ##p<0.01, ###p<0.001, §single vs double 
knockdown, §p<0.05.  
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Start  End    Forward  Reverse  Internal sequencing primers 
Promoter  204380800  204381633    CTCGACGCTTCAACACCA  GGGCATTCAACCTTCCAT     834 
Exon 1  204380426  204381021  CGTCGGGAACTTAGAAGAGC  GACGTAGACGCCCAACAGTC    596 
Exon 1  204379845  204380621  GGAAAGCAGTCCAGGTAGGA  TCTGTAGGCTTCCTCCGAAT    777 
Exon 1  204379186  204379984  CTTCCTCATCCCAATCCTCA  TTGCCCAGTAGCCTTCAATC    799 
Exon 1  204378537  204379351  AAGCCTCCAAAGTCATGCTG  GGAGAGGGCCGAATAAGTGT    815 
Intronb   204376192  204377016  AATAACCACTATATCCCTGGAAGTC  CCTTTGACTACCTGCCATTG    825 
Exon 2  204375199  204375499  CTAGGACTACAGGCTGCCAAC  CCTCAATGCTGATTGTAAGATCC    301 
Exon 2  204374565  204375305  TTGTGGCAGTCCTTGGAAAT  GCTTGACATTTGAACACAGAGA    741 
Exon 2  204374234  204374967  TGACAGTGCTGAGGCATGAT  ATGTCCTTTGCCTGCATGA    734 
Exon 2  204373791  204374484  CCCTGTAAGCACTTCTGATGA  TTTGAAGAGGGTTCTGTGTACG    694 
Exon 2  204372956  204373998  TCCTTTCTGTCCTTCTTATCACC  GCATTGACTGTTTGTGTTTGG  CAGCTTGGAGTGCAGTGG  1043 
Exon 2  204372325  204373064  AAAGCTAGGGCCAATTTCAG  TGGGATTCTAACCTCACTACCAA    740 
aMap position on hg19 reference sequence. bThis intronic region was selected as potentially functionally relevant to PPP1R15B because it shows 
species conservation and includes non-spliced human ESTs. 
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Supplementary Table 2: siRNA sequences 
 
siRNA  Sequence  Company  Validated in 
P1R15B 1  GACUUACUGUUGUACAGCATT  Invitrogen   
P1R15B 2  AAGGGAUGGAUGCAGGUUCCA    (1) 
DP5  UCACAGUUUCUUGGUGCUAAGUGUA  Invitrogen  (2) 
PUMA  ACGAGCGGCGGAGACAAGAAGAGCA  Invitrogen  (3) 
Bim  CGAGGAGGGCGUUUGCAAACGAUUA  Invitrogen  (3) 
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Supplementary Table 3: Primer sequences used for mRNA expression studies 
 
a STD: Standard, RT: Real time  
Gene  STD/RTa  Forward  Reverse  Size 
PPP1R15B  STD  AGGCAGTCAGGCATCCTCT TCAAGTAAGAGATGGAGTGGG  431 
  RT  TGGGTGAGGCACTTTCTGG  TGGCGACTTCTGTTTCCTG 177 
GAPDH  STD  ATGACTCTACCCACGGCAA TGTGAGGGAGATGCTCAGTG  930 
  RT  AGTTCAACGGCACAGTCAA TACTCAGCACCAGCATCACC  136 
DP5  STD  GCACCCTGTGACCTTCCTA TCACATGCACGAACACACAC  550 
  RT  GCCGTGGTGTTACTTGGAC GATTGTGCCAGAGCTTCACA  125 
PUMA  STD  TGGGTGCACTGATGGAGA AACCTATGCAATGGGATGGA  497 
  RT  AGTGCGCCTTCACTTTGG  CAGGAGGCTAGTGGTCAGGT  109 
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Supplementary Table 4: Filtering of variants identified by whole exome sequencing of 








Counts are the number of autosomal variants (SNVs and insertion/deletion variants (indels)) 
identified by Whole Exome Sequencing of the patient compared to the Human Reference 
Genome on UCSC build hg19. The successive filters applied after quality filtering are shown: 
ahomozygous variants, bnonsynonymous variants including missense and nonsense, splice-site 
variants and exonic indels (frameshift and non-shifted), cvariants that were absent in the 
homozygous status in an in-house database, in Exome Variant Server (EVS) and in Exome 
Aggregation Consortium (ExAC) and with a MAF < 0.005 in these databases and in dbSNP.   
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 Supplementary Table 5: Description of the 18 rare variants identified by whole exome sequencing in patient 1, and complementary 
genotyping of these variants in patient 2 
 Genomic map position is on UCSC hg19. Description of the consequences on cDNA and protein follows the Human Genome Variation Society 
(HGVS) recommendations (4).  Heterozygotes and total genotype counts, heterozygotes frequencies, and minor allele frequencies (MAF) are 
given for EVS and ExAC. All the variants were absent in the homozygous status in these databases. The genotype of the two affected siblings is 
shown as 2/2 (homozygous for the rare allele), 1/2 (heterozygous) and 1/1 (homozygous for the frequent allele, none found). Variants 



















chr1:150532595G>A  ADAMTSL4  NM_019032  c.3384G>A  NP_061905  p.Val1050Ile  rs201941243  Absent  0  9/60664 (0.00015)  0.00007  2/2   2/2 
chr1:152285138A>G  FLG  NM_002016  c.2262T>C  NP_002007  p.Ser742Pro  NA  Absent  0  2/60705 (0.00003)  0.00002  2/2   2/2 
chr1:200972760C>A  KIF21B  NM_017596  c.1485G>T  NP_060066  p.Arg389Leu  NA  Absent  0  Absent  0  2/2   2/2 
chr1:204375390G>A  PPP1R15B  NM_032833  c.2379C>T  NP_116222  p.Arg658Cys  NA  Absent  0  Absent  0  2/2   2/2 
chr1:205632155G>A  SLC45A3  NM_033102  c.1105C>T  NP_149093  p.Ala255Val  rs142713511  3/6492 (0.00046)  0.00023  19/57327 (0.00033)  0.00017  2/2   2/2 
chr10:79601934T>C  DLG5  NM_004747  c.1214A>G  NP_004738  p.His381Arg  rs150885638  9/6503 (0.0014)  0.00069  68/60227 (0.0011)  0.00056  2/2   1/2 
chr11:6646598C>T  DCHS1  NM_003737  c.7380G>A  NP_003728  p.Arg2326His  NA  Absent  0  1/60150 (0.00002)  0.00001  2/2   1/2 
chr16:1719068C>T  CRAMP1L  NM_020825  c.3401C>T  NP_065876  p.Pro1134Leu  NA  Absent  0  2/55044 (0.00004)  0.00002  2/2   1/2 
chr16:1967936T>C  HS3ST6  NM_001009606  c.298A>G  NP_001009606 p.Thryr99Cys  NA  Absent  0  Absent  0  2/2   1/2 
chr16:2816615 G>A  SRRM2  NM_016333  c.6635G>A  NP_057417  p.Arg2029His  NA  Absent  0  6/60547 (0.00010)  0.00005  2/2   1/2 
chr18:8784555C>T  MTCL1  NM_015210  c.1587C>T  NP_056025  p.Ala482Val  rs115077293  13/6502 (0.0020)  0  57/56978 (0.0010)  0.00050  2/2   1/2 
chr19:2807595C>T  THOP1  NM_003249  c.1197C>T  NP_003240  p.Arg348Cys  NA  Absent  0  3/58471 (0.00005)  0.00003  2/2   1/2 
chr19:2851553C>T  ZNF555  NM_152791  c.356C>T  NP_001166246 p.Thr73Met  rs369544612  2/6503 (0.00031)  0  8/60476 (0.00013)  0.00007  2/2   1/2 
chr2:210742714G>C  UNC80  NM_032504  c.3963G>C  NP_115893  p.Glu1295Gln  rs187089611  Absent  0  4/10840 (0.00037)  0.00018  2/2   2/2 
chr3:133474254A>G  TF  NM_001063  c.858A>G  NP_001054  p.Thr184Ala  rs139768770  3/6503 (0.00046)  0.00023  14/60704 (0.00023)  0.00012  2/2   1/2 
chr3:133647257A>G  C3orf36  NM_025041  c.1402T>C  NP_079317  p.Ser131Pro  rs149002991  1/6503 (0.00015)  0.00008  4/60232 (0.00007)  0.00003  2/2   1/2 
chr5 :169310284C>A  FAM196B  NM_001129891  c.2003G>T  NP_001123363 p.Asp207Tyr  rs200832892  Absent  0  15/10832 (0.0014)  0.00069  2/2   1/2 
chr8 :23560457A>G  NKX2‐6  NM_001136271  c.226T>C  NP_001129743 p.Leu56Pro  NA  Absent  0  Absent  0  2/2   1/2 
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Supplementary Table 6: Functional predictions of the variants compatible with mutation status and human mutations and knockout 





























































































In silico prediction of the impact and severity of mutation on protein function was performed using Polyphen-2 (8), SIFT and Provean (9), using 
recommended parameters. Polyphen-2 predictions were made based on the HumDiv model. aHuman islet expression is based on (10) and our 
unpublished data (M.C.) and is given in RPKM (reads per kilobase of exon model per million mapped reads) units. bKnockout mouse model 
phenotype information is according to the Mouse Genome informatics (MGI) and the Wellcome Trust Sanger Institute (WTSI) databases. NA: 
not available.
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Supplementary Figure 1: Heatmap of gene expression in human tissues. RNAseq values 
(in RPKM) from the indicated human tissues were obtained from GTEx (v4.p1). RNA-seq 
data of FACS-purified human islet β-cells were from Nica et al (11). Human islet RNA-seq 
data (24 in total) were from Eizirik et al and Cnop et al (10;12) (and unpublished data). Bone 
(osteoblast) gene expression was obtained from GEO dataset accession number GSE57925 
(unpublished data). The median RPKM value of the samples is represented, with the 
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Supplementary Figure 2: PPP1R15B silencing does not modify expression of the pro-
apoptotic Bim splice variants Bim-EL and Bim-L or the anti-apoptotic proteins BCL2 
and BCL-XL. INS-1E cells were transfected with control siRNA (siCT) or two different 
siRNAs targeting PPP1R15B (siP1R15B1 and siP1R15B2). 48h after transfection the Bim-EL 
and Bim-L (A, B, C) and BCL2 and BCL-XL (D, E, F) expression was examined by Western 
blot. A and D are representative blots of 5 experiments. B, C, E and F are densitometric 
quantifications of protein expression corrected for α-tubulin, and expressed as fold of siCT.  
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